Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 8/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | SELL | P14151 | 1/20 | 0.32 |
| ▸ | SELP | P16109 | 1/20 | 0.32 |
| ▸ | SELE | P16581 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19322647 | 0.83 | TYMP (0.33) | RAPGEF4MEN1NPC1LMNAHTT | |
| SCHEMBL19807357 | 0.83 | AHR (0.40) | RAPGEF4MEN1NPC1LMNAHTT | |
| SCHEMBL26234359 | 0.82 | NMT1 (0.37) | HDAC1HDAC6MEN1LMNAHTT | |
| SCHEMBL30668 | 0.80 | HDAC1 (0.48) | RAPGEF4HDAC1HDAC6SELLSELP | |
| SCHEMBL1004002 | 0.80 | ACHE (0.40) | RAPGEF4SELLSELPSELEACHE | |
| SCHEMBL16373692 | 0.79 | RAPGEF4 (0.39) | RAPGEF4HDAC1HDAC6SELLSELP | |
| SCHEMBL16545830 | 0.79 | RAPGEF4 (0.39) | RAPGEF4SELLSELPSELEMEN1 | |
| SCHEMBL12121733 | 0.79 | RAPGEF4 (0.35) | RAPGEF4HDAC1HDAC6 | |
| SCHEMBL21728879 | 0.79 | ALDH1A1 (0.41) | RAPGEF4HDAC1HDAC6MEN1NPC1 | |
| SCHEMBL19853528 | 0.78 | HDAC1 (0.33) | RAPGEF4HDAC1HDAC6MEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 279 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240072425-A1 | AROMATIC ISOTHIOCYANATES | MERCK PATENT GMBH (DE) | 2024-02-29 | — | — | US | disclosed |
| US-20240072425-A1 | AROMATIC ISOTHIOCYANATES | MERCK PATENT GMBH (DE) | 2024-02-29 | — | — | US | disclosed |
| US-11834599-B2 | Aromatic isothiocyanates | MERCK PATENT GMBH (DE) | 2023-12-05 | — | — | US | disclosed |
| US-11834599-B2 | Aromatic isothiocyanates | MERCK PATENT GMBH (DE) | 2023-12-05 | — | — | US | disclosed |
| US-20230313043-A1 | OPTICAL COMPONENT | MERCK PATENT GMBH (DE) | 2023-10-05 | — | — | US | disclosed |
| WO-2023117724-A1 | ISOTHIOCYANATOETHYNYLBENZENE DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-06-29 | — | — | WO | disclosed |
| EP-3507275-B1 | CXCR3 RECEPTOR AGONISTS | RECEPTOS LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| WO-2022129018-A1 | HETEROAROMATIC ISOTHIOCYANATES | MERCK PATENT GMBH (DE) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022128845-A1 | HETEROAROMATIC ISOTHIOCYANATES | MERCK PATENT GMBH (DE) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022090099-A1 | AROMATIC ISOTHIOCYANATES | MERCK PATENT GMBH (DE) | 2022-05-05 | — | — | WO | disclosed |
| US-7314874-B2 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide;modified amidine elements of high potency in vitro, excellent pharmacological and pharmaceutical properties in vivo | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-7285565-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| US-7285565-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| EP-1762605-A1 | Naphthalene compound with terminal hydrogen, liquid crystal composition including the compound, and LCD device including the liquid crystal composition | Chisso Petrochemial Corporation (JP) | 2007-03-14 | — | — | EP | disclosed |
| US-20070051919-A1 | NAPHTHALENE COMPOUND WITH TERMINAL HYDROGEN, LIQUID CRYSTAL COMPOSITION INCLUDING THE COMPOUND, AND LCD DEVICE INCLUDING THE LIQUID CRYSTAL COMPOSITION | CHISSO PETROCHEMICAL CORPORATION (JP) | 2007-03-08 | — | — | US | disclosed |
| US-20070051919-A1 | NAPHTHALENE COMPOUND WITH TERMINAL HYDROGEN, LIQUID CRYSTAL COMPOSITION INCLUDING THE COMPOUND, AND LCD DEVICE INCLUDING THE LIQUID CRYSTAL COMPOSITION | CHISSO PETROCHEMICAL CORPORATION (JP) | 2007-03-08 | — | — | US | disclosed |
| US-20070021472-A1 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility | MILLENNIUM PHARMACEUTICALS, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070021472-A1 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility | MILLENNIUM PHARMACEUTICALS, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20040116399-A1 | Inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-17 | — | — | US | disclosed |
| US-20040116399-A1 | Inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070051919-A1 | NAPHTHALENE COMPOUND WITH TERMINAL HYDROGEN, LIQUID CRYSTAL COMPOSITION INCLUDING THE COMPOUND, AND LCD DEVICE INCLUDING THE LIQUID CRYSTAL COMPOSITION | LEF1, CFD, FOXO1 | RAPGEF4 3777/4885HDAC1 2263/4885HDAC6 3099/4885 |
| US-20240072425-A1 | AROMATIC ISOTHIOCYANATES | TRPA1, TRPC1, CRY1 | RAPGEF4 2669/4885HDAC1 1957/4885HDAC6 2436/4885 |
| US-20070021472-A1 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility | F2, TFPI, PLG | RAPGEF4 3414/4885HDAC1 193/4885HDAC6 810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.